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Abstract: Non-communicable diseases (NCDs) such as cancer, diabetes, and chronic respiratory
and cardiovascular diseases continue to be threatening and deadly to human kind. Resistance to
and side effects of known drugs for treatment further increase the threat, while at the same time
leaving scientists to search for alternative sources from nature, especially from plants. Pentacyclic
triterpenoids (PT) from medicinal plants have been identified as one class of secondary metabolites
that could play a critical role in the treatment and management of several NCDs. One of such
PT is ursolic acid (UA, 3 β-hydroxy-urs-12-en-28-oic acid), which possesses important biological
effects, including anti-inflammatory, anticancer, antidiabetic, antioxidant and antibacterial effects,
but its bioavailability and solubility limits its clinical application. Mimusops caffra, Ilex paraguarieni,
and Glechoma hederacea, have been reported as major sources of UA. The chemistry of UA has
been studied extensively based on the literature, with modifications mostly having been made at
positions C-3 (hydroxyl), C12-C13 (double bonds) and C-28 (carboxylic acid), leading to several UA
derivatives (esters, amides, oxadiazole quinolone, etc.) with enhanced potency, bioavailability and
water solubility. This article comprehensively reviews the information that has become available over
the last decade with respect to the sources, chemistry, biological potency and clinical trials of UA and
its derivatives as potential therapeutic agents, with a focus on addressing NCDs.
Keywords: non-communicable diseases; pentacyclic triterpenoids; ursolic acid; derivatives; sources;
biological studies; clinical trials.
1. Introduction
Non-communicable diseases (NCDs), including cancers, cardiovascular diseases, pulmonary
illnesses, and diabetes, account for nearly 71 percent of all fatalities globally, as reported by the World
Health Organization. The rapid increase of NCDs has been influenced by a series of flexible behavioural
threat variables, including unhealthy eating habits, physical inactivity, cigarette smoke exposure and
damaging use of alcoholic drinks, as well as natural air pollutants, metabolic (hypertension, obesity,
hyperglycaemia, hypercholesterolemia) and occupational (gases, carcinogens, fumes, particulates)
risks [1].
On the other hand, natural products have been recognized in therapeutic drugs for many years as an
essential source of active substances. Therapeutic agent complexity depends on synthetically prepared
chemical combinations. Therapeutic drugs are regarded to be natural, synthetic or semi-synthetic,
depending on the source from which they have been derived. Natural therapeutic agents are made
from naturally occurring compounds that contain active ingredients extracted from sources such as
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plants [2]. One group of compounds from plants is called pentacyclic triterpenoids (PT). These are
defined as a group of 30 carbon structural compounds with interesting biological activities and great
diversity, with more than 100 chemical skeletons of carbon. PT, which have been studied for over
two decades, with a perceptible increase in their pharmacological significance, are described to have
strong health benefits, including hepatoprotective, wound healing, antibacterial, anti-inflammatory,
antitumoral, and antiviral properties, together with their low toxicity [3]. PT are used in treatment
of several cancers without damaging normal cells through toxicity [4]. These PT have also revealed
therapeutic and chemical preventive characteristics in skin, lung, liver and lung disease [5]. The
consumption of vegetables and fruit by animals is thought to have a reduced incidence of cancer and
several illnesses. PT have been separated and elucidated from various plants [6]. Oleanolic acid (OA),
ursolic acid (UA) (1), betulinic acid (BA), and lanosterol are examples of PT [7,8]. Triterpene groups,
along with their classified chemical compounds and their characteristics, are shown in Table 1. For
interesting chemical structures of pentacyclic triterpenoids such as UA, their reactivity and interactions
with a disease are essential for searching through effective drug sites. Many triterpenes can be used as
bioactive compounds immediately or modified to enhance their potency and selectivity [9]. Therefore,
this review provides an overview of the structural development of UA and its derivatives, along with
their advantages as anti-cancer, anti-inflammatory, antibacterial, anti-diabetic and neuroprotective
therapeutic agents, as well as their herbicidal activities.
Table 1. Pentacyclic triterpene compounds from plant sources with their chemical characteristics.
Pentacyclic
Triterpenes Compound
Chemical
Formula
Molecular Mass
(g/mol) Reference(s)
ursane ursolic acid C30H48O3 456.71 [7,10–15]
uvaol C30H50O2 442.72 [16–18]
α-amyrin C30H50O 426.70 [17–20]
oleanane oleanolic acid C30H48O3 456.71 [13–15,20–23]
maslinic acid C30H48O4 472.70 [20,22,24]
β-amyrin C30H50O 442.70 [18,20,25]
erythrodiol C30H50O2 442.72 [17,18,20]
lupane lupeol C30H50O 426.70 [15,20,26–34]
betulin C30H50O2 442.72 [15,17]
betulinic acid C30H48O3 456.71 [15,17,26,35–37]
dammarane dammarane C30H54 414.75 [38–40]
pseudojujubogenin-3-o-β-d-
glucopyranoside C36H58O10 650.85 [41]
hopane C30H52 412.75 [38,42]
diploptene C30H50 410.73 [43,44]
bacteriohopanetetrol C35H62O4 546.89 [43,45]
sterols cholesterol C27H46O 386.65 [46]
ergosterol C28H44O 396.65 [43]
β-sitosterol C29H50O 414.71 [47–50]
2. Chemistry of UA
Ursolic acid (3 β-hydroxy-urs-12-en-28-oic acid) is a pentacyclic triterpenoid composed of a C-30
chemical structure built from isoprenoid units with A, B, C, D and E rings (Figure 1) [51]. UA may
occur as an aglycone or free acid of saponins [52,53]. UA has a low solubility in water, but high
solubility in alcoholic sodium hydroxide (NaOH) and glacial acetic acid [54–57]. The UA chemical
formula is C30H48O3, with a melting point of 283–285 ◦C. The properties of the UA structure indicate
that it has a molecular weight of 456.7g/mol [20,52,53,58]. UA is mainly biosynthesized by folding
and cycling squalene from a dammarenyl cation, which makes the third UA ring by expanding the
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ring and creating an added ring [58]. The biosynthesis of UA found in plant cells originates from the
cyclical (3S)-oxidosqualene cycling. The predominant (3S)-oxidosqualene predecessor is converted
into a cationic dammarenyl structure undergoing chain growth and other cyclic changes in order to
form this third distinct ring, which is present in the α-amyrin skeleton, a nucleus in the UA [51].
Figure 1. Ursolic acid chemical structure.
It is well known that low aqueous solubility of a drug may seriously affect its medication
effectiveness. It has also been documented that certain treatments have a low solubility and few side
effects. Ursolic acid, however, has low water solubility, which limits bioavailability in the human
body [59]. The limited solubility, poor bioavailability and rapid metabolism of UA have limited their
additional clinical applications for therapeutic effect in numerous diseases. Hence, many researchers in
recent years have reported various modifications in an attempt to improve UA pentacyclic triterpenoids’
potency, solubility and bioavailability in water [59,60]. Hence, this review focuses on some of the
recent modifications to UA aiming at their use as bioactive agents with promising therapeutic effects of
non-communicable diseases.
The chemical modifications to date have focused mainly on the hydroxyl group at position C-3,
the unsaturated double bond at position C12-C13, and the carboxylic acid at position C-28 at rings
A, C and E, respectively, as displayed in Figure 1 [61]. Mostly, structural modifications were made
to above-mentioned positions in an effort to enhance the potency and bioavailability of UA and its
derivatives, and study their structure-activity relationships and mechanisms [62]. For this reason,
researchers started the search for new novel derivatives of through modifications of chemical groups
in UA. Shao and colleagues (2011) in their UA (1) structure-activity relationship synthesized a total of
twenty-three analogues through modification at position C-3 and C-28. 3-O-acetylursolic acid was
obtained from acetylation of UA, which was later treated with bromo-diolefine to yield fatty esters as
shown in Figure 2. They further synthesized UA amides and ester derivatives (Figure 3) [60].
Batra and Sastry (2013) reported isolation of UA (1) from Ocimum sanctum, which led to the
preparation of three derivatives, namely, 3β-acetoxy-urs-12-en-28-oic acid (25), [N-(3β-acetoxy-urs-
11-oxo-12-en-28-acyl) aniline] (26) and [Methyl N-(3β-butyryloxyl-urs-12-en-28-oyl)-2-amine acetate]
(27) as shown in Figure 4 [63].
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Figure 2. Preparation of UA ester derivatives. Reagents and conditions: (a) CH3(CH2)nBr,
potassium carbonate (K2CO3), dimethylformamide ((CH3)2NCH); (b) Br(CH2)nBr, K2CO3, (CH3)2NCH;
(c) Acetonitrile CH3CN/silver nitrate (AgNO3), COO(CH2)nBr. 2: R1 = CH2CH3; 3: R1 = (CH2)2CH3; 4:
R1 = (CH2)3CH3; 5: R2 = (CH2)2ONO2; 6: R2 = (CH2)3ONO2; 7: R2 = (CH2)4ONO2.
Nascimento and colleagues (2014) semi-synthesized two analogues of UA isolated from the
Sambucus australis plant. Modifications to the UA structure were made at C-3 (hydroxyl group) in
order to yield 3β-formyloxy-urs-12-en-28-oic acid (19) and 3β-acetoxy-urs-12-en-28-oic acid (20) [64].
In order to examine the effective locations, Meng and collaborators (2017) discovered a number
of exciting ursolic UA derivatives. They developed and evaluated 11 derivatives (30–41) (Figure 5,
Figure 6, Table 2). They found that the inclusion of an acetyl group at C-3 and an amino alkyl at C28
increased biological potential [65].
Sahni and others (2016) reported the isolation of UA from acetone extract of a Eucalyptus hybrid.
In an attempt to increase the potency of UA, these authors synthesized a total of 6 compounds (esters
and amide) at positions C-3 and C-28 (Figure 7). In the preparation of methyl (42), ethyl (43) and propyl
esters (44), UA was treated with acetic anhydride, butyril chloride, and propyl chloride at position C-3
respectively in the presence of DMAP and THF catalysts. C-17 methyl ester (45) was developed by
treating UA with methyl iodide and modifying the C28 carboxylic acid group. A C-17 propyl amine
(46) variant was prepared by the oxalyl chloride treatment of UA in the presence of CH2Cl2 and then
propyl amine [66].
Wu and colleagues (2017) produced several UA derivatives (47–61) in an effort to study the
greater power and bioavailability of the UA by adding an acyl group at position C-3 to make the
most of the structure-activity relationship. They further synthesized ester derivatives by a process of
esterification with suitable acid chlorides in the presence of a DMAP catalyst. In addition, Claisen
Schmidt condensation and Jones oxidation steps at positions C-2 and C-3, respectively, were used for
bioactive UA derivatives (Figure 8) [62].
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Figure 3. Modification of UA yielded amides and ester derivatives. Reagents and conditions: (d)
anhydride/Pyridine/N, N-dimethyl-4-aminopyridine (DMAP); (e) CH3(CH2)nBr, K2CO3, (CH3)2NCH;
(f) rhodium carbonyl chloride ((CO)2Cl), dichloromethane (CH2Cl2); (g) CH2Cl2, triethylamine (Et3N),
HR; (h) NaOH, methanol (CH3OH)/tetrahydrofuran (THF). All the reactions were carried out at
room temperature.
Table 2. Some novel analogues derived, corresponding with Figure 6, above.
Compound Number R1 R2 R3
1 OH - -
30 OCH3 CHO -
31 OC2H5 CHO -
32 OCH(CH3)2 CHO -
33 CHO -
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Table 2. Cont.
Compound Number R1 R2 R3
34 CHO -
35 OCH2CH2CH3 CHO -
36 OH - OCOCH3
37 Cl - OCOCH3
38 - OCOCH3
39 - OCOCH3
40 - OCOCH3
41 - OCOCH3
Figure 4. Some of UA derivatives. 1, 25–27; 1: R1 = H; R2 = H; R3 = OH; 25: R1 = OCCH3; R2
= H; R3=OH; 26: R1 = OCCH3; R2 = O; R3 = NHC6H5; 27: R1 = OCH2CH2CH3; R2 = H; R3 =
NHCH2CO2CH3.
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Figure 5. UA analogues. 28–29; 28: R = COH; 29: R = COCH3.
Figure 6. Derivatives synthesized from UA.
Figure 7. Synthesized UA derivatives. 42–46; 42: R1 = COCH3; R2=OH; 43: R1 = COCH2CH3; R2 =
OH; 44: R1 = COCH2CH2CH3; R2 = OH; 5: R1 = H; R2 = OCH3; 46: R1 = H; R2 = NHCH2CH2CH3.
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Figure 8. Synthesis of UA derivatives; reagents and conditions: (a) acid chloride or anhydride, DMAP,
pyridine, reflux; (b) chromium (III) oxide (CrO3), sulphuric acid (H2SO4), acetone, 0 ◦C, 1 h; (c) R1-CHO,
potassium hydroxide (KOH), ethanol, room temperature.
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Figure 9. Cont.
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Figure 9. Some reported UA analogues.
In a separate study, Wu and colleagues (2015) synthesized and elucidated several UA derivatives
(62–78) as displayed in Figure 9. These researchers explored the structure-activity relationship of the
synthesized bioactive analogues. They mainly focused their modifications on hydroxyl position C-3
and carboxylic group C-17 of the UA parent compound to produce a series of derivatives. In the
first step, 3-O-acetate derivative was developed by the addition of acetic anhydride in anhydrous
pyridine, which was later treated with oxalyl chloride to yield the 28-acyl-chloride intermediate.
They further dissolved the intermediate in dichloromethane to give a series of amino compounds
including aminobenzene, p-fluoroaniline, p-chloroaniline, p-bromobenzenamine, p-methoxylaniline
o-fluoroaniline, o-chloroaniline and o-bromobenzenamine through condensation in the presence of
triethylamine. After this, saponification analogues (62–69) were produced, which were later hydrolysed
to give more derivatives (70–77). Lastly, the 3-oxo anlogue (78) was developed through oxidation
with pyridinium chlorochromate. All the structure of these UA derivatives were elucidated by a
series of spectroscopic techniques, such as nuclear magnetic resonance (NMR) including 13C-NMR
and 1H-NMR with melting point, high resolution mass spectrometry, and electrospray ionization mass
spectrometry (ESI-MS) [67].
Several UA-derived compounds have been developed with the aim of improving their potency
and selectivity. Gu and others (2017) synthesized an interesting series of UA derivatives containing
oxadiazole and quinoline chemical groups. One analogue is 3-oxo-ursolic acid (78) (78% yield),
which was prepared by dissolving UA in acetone solvent and later oxidized using Jones reagent,
focussing on position C-3. More derivatives (79–82) (62–68% yield) were synthesized by reacting
3-oxo-ursolic acid with corresponding o-aminobenzaldehyde under nitrogen (N2) molecule atmospheric
conditions, as shown in Figure 10. Compound (79) was synthesized by reacting 3-oxo-ursolic acid with
o-aminobenzaldehyde according the Friedlander reaction. Afterwards, 28-acylchloride derivatives
were prepared by treating compound (79–82) with thionyl chloride. Furthermore, 28-acylchloride
derivatives were treated with aryl hydrazine in the presence of trimethylamine (EtN3) to yield 83–94
(47–48% yield). Meanwhile, the dehydration condensation of 83–94 yielded oxadiazole derivatives
(95–106) (56–74% yield), as shown in Figure 10. All of these compounds were purified through
column chromatography and elucidated by different spectroscopic techniques including infrared (IR),
13C-NMR, 1H-NMR, ESI-MS and elementary analysis [68].
Many researchers, in search of more bioactive compounds, have reported different UA derivatives.
Herewith are some of UA analogues with interesting mechanisms related to currently existing
non-communicable diseases utilizing positions C-2, C-3, C-20 and C-28 (Figure 11) [69–73]. One UA
derivative compound, 118 (2α,3β,7β,23-tetrahydroxyurs-12-ene-28-oic acid) (Figure 11), is a naturally
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occurring compound isolated from Castanea crenata Sieb. et Zucc. This compound was elucidated
using several spectroscopic techniques, including IR, 1H-NMR, 13C-NMR, and HR-ESI MS [74].
Figure 10. Summary of reaction scheme to yield UA analogues (78–106). Reagents and conditions:
(a) Jones reagent, acetone at 0 ◦C for 5 h; (b) ethanol, substituted oaminobenzaldehyde, potassium
hydroxide (KOH), reflux under N2 atmospheric conditions for 24 h; (c) Thionyl chloride (SOCl2),
benzene, reflux for 3 h; RCONHNH2, trimethylamine (Et3N), dichloromethane (CH2Cl2)/ether at room
temperature for 8–12 h; (d) p-Toluenesulfonic acid (TsOH), toluene, reflux for 6 h.
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Figure 11. Cont.
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Figure 11. Some derivatives prepared by modification of UA with interesting potential as therapeutic
agents.
3. Sources of UA and Its Biological Potency
Ursolic acid is a five-membered ring extensively distributed in food, medicinal herbs, fruit,
vegetables, etc. [19,75–82]. UA triterpenoid is well documented to be available in fruits such
as cranberries (Vaccinium macrocarpon) [53,83], blueberry (Vaccinium spp.) [77], basil (Ocimum
basilicum) [78,84], olive (Olea europaea) [20], heather flower (Calluna vulgaris) [79], pear (Pyrus pyrifolia),
Labrador tea (Ledum groenlandicum Retzius) [77], rosemary (Rosmarinus officinalis) [65] and apple peels,
which possess important health benefits. UA is also distributed among higher plants, such as Mimusops
caffra, Ilex paraguarieni, Glechoma hederaceaes, Ichnocarpus frutescens, and Syzygium claviflorum [19,77,80].
More plants sources, quantities of UA and its biological applications are hereby reported in Table 3.
UA has been investigated and is reported to possess many health benefits, including anti-apoptotic,
anti-carcinogenic, anti-inflammatory, antioxidant, antirheumatic, antiviral, antitumoral, trypanocidal,
etc. [61,62,78]. UA also has health benefits, and there are many reports of its anticancer activity in
several cancers, including breast, skin, lung, prostate and pancreatic cancers [19,20,63]. Due to its
low toxicity, anticancer activities, and commercial availability with various structural modifications,
UA is regarded as a pillar through organic semi-synthesis, and this has attracted more researchers
to studying and discovering various ursolic acid derivatives [61]. UA is popular because of its
antiproliferative properties, inducement of cancer apoptosis, prevention of tumorigenesis, and/or
blocking of the cell cycle in cancer cells. This was evident in the observation from one apoptosis
mechanism which showed UA to have the ability to prevent Nuclear Factor κB (NF-κB) pathway by p65
phosphorylation suppression, resulting in mandatory decrease in various downstream oncogenes such
as B-cell lymphoma-extra-large (Bcl-XL) and B-cell lymphoma-2 (Bcl2). Nonetheless, the antitumor
potency of UA is poor because of its lower solubility, which decreases the drug absorption in the
human system, leading to challenges in obtaining its full benefits. Therefore, it is necessary to
construct its derivatives through semi-synthetic modifications in order to improve its antitumor activity.
Mostly, the modifications of ursolic acid occur at sites C-3, C12-C13, and at position C-28 [59,63,64,72].
Jiménez-Arellanes and colleagues (2013) reported antimicrobial activity of pentacyclic triterpenoid
compounds, namely, UA against Mycobacterium tuberculosis H37Rv [85]. Ursolic acid has been
investigated in different stages of clinical trials for its therapeutic effects and selectivity against a
diversity of diseases [86].
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Table 3. Sources of UA with their biological properties.
Plants Species
(Family)
Plant Part
(Solvent Crude
Fraction)
UA Content
(mg or g)
Type of
Study Biological Effects Reference(s)
Fragrae fragrans
(Gentianaceae) fruits (methanol) 91 g in vitro antiproliferation [14]
Saurauja
roxburghii
(Actinidiaceae)
leaves (methanol) nr in vitro cytotoxicityagainstglioma cells [10]
Ocimum sanctum
(Lamiaceae)
whole plant
(methanol,
acetone,
acetonitrile and
ethyl acetate)
11.21 mg in vitro anticancer andantiproliferation [63,87,88]
Eucalyptus
(Myrtaceae) leaves (acetone) nr in vivo
neuro-protective
agent [66,75,89]
Malus pumila
(Rosaceae) fruits nr in vitro antitumor [79]
Tribulus arabicus
(Zygophyllaceae)
aerial parts
(ethanol) 1 g
in vitro and
in vivo
antihyperuricemic
activity [90]
Panax ginseng
(Araliaceae) roots nr in vivo
antihypertensive,
antihyperlipidemic
and antioxidant
effects
[91]
Bursera cuneata
(Burseraceae)
aerial parts
(dichloromethane) 33.3 mg
in vitro and
in vivo
anti-inflammatory
and antihistaminic
activity
[92]
Sambucus
australis
(Adoxaceae)
aerial parts
(ethanol) 180 mg in vitro
antibacterial and
antioxidant [64]
nr = not reported.
4. Biological Effects and Clinical Trials of UA and Some Derivatives
4.1. Anti-Inflammatory
Pathogenesis and homeostasis are part of inflammation. The inflammatory response is initiated
after harm and/or microbial invasion to recover homeostatic tissue balance between composition
and physiological function. Persistent inflammation may lead to damage of tissues, resulting in
non-functioning organs [93]. Inflammation is a complicated occurrence linked to the development of
different diseases, such as cardiovascular and neurodegenerative diseases, and cancer [55]. Rudolf
Virchow proposed the link between inflammation and cancer as early as 1863. Currently, acute
inflammation, with concomitant cytokine activity and enhanced output of reactive oxygen species, is
identified as a cancer-promoting disease [3,16]. Zerin and co-authors (2016) examined the capacity of
UA to decrease the production of TNF-α in RAW 267.4 and A549 cells infected with Mycobacterium
tuberculosis and Con A-stimulated mouse splenocytes to detect anti-inflammatory activity. TNF-α is
pivotal to inflammation and its impact on IL-1β and IL-6 decrease has been examined under comparable
circumstances of therapy. These authors also studied UA activity with the aim of decreasing the
levels of inflammatory intercessor, cyclooxygenase 2 and NO synthase found in stimulated cells. UA
exhibited significant inhibitory effects on cytokine expression levels, immunomodulatory mediators,
and release of NO. It is suggested that this compound can be used for tuberculosis and antibiotic
therapy because of the UA anti-inflammatory potency in the mentioned cells [94]. Huang and others
(2016) reported a similar study in which in vitro inhibition of cyclooxygenase-2 activity was due
to active compounds (UA, cis-hydroxycinnamoyl ursolic acid and trans-hydroxycinnamoyl ursolic
acid) and cranberry extracts [73]. Forbes and co-workers (2009) synthesized eight derivatives, with 4
showing promising anti-inflammatory and antioxidant activity (50% lipid peroxidation inhibition at
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25 µg/mL). The anti-inflammatory activity was tested through the use of enzyme inhibitory assays
referred to as in vitro cyclooxegenase-1 (COX-1) and cyclooxegenase-2 (COX-2) [95].
Wei and collaborators (2018) recorded and assessed for anti-inflammatory action the synthesis
of 20 UA derivatives comprising oxadiazole, triazolone, and piperazine moieties. Compound (115)
(Figure 11) displayed the most potent ear inflammation efficacy of all the synthetic compounds (69.76%),
which was greater than ibuprofen (25.17%) and indomethacin (26.83%) at 100 mg/kg (i.p.), and was
1- and 2-fold more powerful than conventional medicines. The MTT assay evaluated the cytotoxicity
of the compounds and, in contrast to UA, no compounds were reported to show any significant
cytotoxic behaviour (IC50 > 100 µmol/L). In addition, the molecular docking findings stated that
the UA derivatives showed elevated attraction for effective COX-2 location, potentially exhibiting
anti-inflammatory potency through COX-2 inhibition. The findings from this study provide information
about UA and its derivatives as anti-inflammatory agents, which could lead to the development of
potentially new and safe COX-2 inhibitors [96].
4.2. Anticancer Activity
In recent memory, cancer has been ranked as the top deadly diseases and is responsible for
many deaths worldwide, being ranked second in economically developed countries. With several
forms of cancer being poorly controlled through treatments that have serious side effects themselves
and the inevitable limitations of cancer screening programs, chemoprevention and its potential have
generated great hope and interest over the past decades [97]. Batra and Sastry (2013) reported isolation
of UA (1) (Figure 1) from Ocimum sanctum, which led to the preparation of three novel derivatives
from 3β-acetoxy-urs-12-en-28-oic acid [N-(3β-acetoxy-urs-11-oxo-12-en-28-acyl) aniline and [Methyl
N-(3β-butyryloxyl-urs-12-en-28-oyl)-2-amine acetate] with high in vitro anticancer potency when
compared to the ursolic acid parent compound. The modifications of compound 1 occurred at
hydroxyl C3, C-11, and carboxylic C-28, as shown in Figure 4. Compounds 2, 3 and 4 showed potent
anti-proliferation activity in cancer cells, with compound 3 displaying higher significance [63].
Meng and colleagues (2017) reported interesting ursolic acid novel derivatives. These authors
prepared and synthesized eleven derivatives, which were later assessed for their antitumor inhibition
and cytotoxicity against numerous cell lines developed by cancer such as HepG2, cervical carcinoma
(HeLa) and BGC-823 using MTT assay. The modifications occurred in positions C-2, C-3 and C-28 to
yield 12 compounds (5–17), as shown in Figure 5. Compound 15 [IC50 = 9.25 (HeLa), 21.2 (HepG2)
and 8.06 µmol/L (BGC-823)] and compound 16 [IC50 = 13.8 (HeLa), 23.7 (HepG2) and 9.15 µmol/L
(BGC-823)] were more significant because of their evident high antitumor inhibition against cancer
cells. This led to a belief that the antitumor properties of the mentioned compounds could be attributed
to the substitution made during the synthesis modification of UA; electron withdrawing, alkanoyloxy
imino chain at position C-2, and alkyl side chains at position C-3 [65].
In a different investigation, Shao and co-authors (2011) explored the in vivo and in vitro anticancer
activity of a number of synthesized UA derivatives. The synthesized compounds were evaluated
against various cancer cells of BGC-823, SH-SY5Y, HELF, HeLa and HepG2 by the assay called
MTT. N-[3β-acetoxy-urs-12-en-28-oyl]-2-aminodiethanol, N-[3b-acetoxy-urs-12-en-28-oyl]-amino-N-(2-
hydroxyethyl) piperazine, N-[3b-acetoxy-urs-12-en-28-oyl]-amino-1-hydroxyethylethoxy piperazine and
N-[3b-acetoxy-urs-12-en-28-oyl]-amino-4-piperidineethanol exhibited better in vitro antiproliferative
activity. The N-[3β-acetoxy-urs-12-en-28-oyl]-2-aminodiethanol derivative was reported to have
anticancer activity (45 ± 4.3%) on Kunming mice compared to the control group [60]. Rashid and others
(2013) produced several derivatives of ursolic acid-triazolyl. The antitumor potency of these compounds
was assessed against a number of individual cancer cells, including leukaemia (THP-1), heart (MCF-7),
colon (HCT-116), pulmonary (A-549) and ordinary adult epithelial cells (FR-2) using sulforhodamine-B
testing. The antitumor potencies of four UA-derivatives against the above-mentioned cells were
observed [98]. More authors have reported on ursolic acid and its derivatives as anticancer agents.
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In an attempt to develop new anticancer agents, Gu and co-authors (2017) proposed a series
of quinoline and oxidiazole derivatives of UA. These researchers evaluated the cytotoxicity of
synthesized derivatives against cancer cell lines such as human breast (MDA-MB-231), heptacarcinoma
(SMMC-7721), HeLa and normal hepatocyte cell lines (QSG-7701) using MTT assay. The cancer
drug atoposide was used as a positive control. The results from this particular study showed
interesting significant effects of UA derivatives (79–82, 91, 97) against at least one of the cancer cell
lines (MDA-MB-231, SMMC-7721 and HeLa) (IC50 < 10µM). Compound 79 showed a higher potency
compared to the positive control, with IC50 values of 12.49 ± 0.08, 0.36 ± 0.05, and 0.61 ± 0.07 µM
against SMMC-7721, HeLa and MDA-MB-231 cell lines, respectively. The bioactive derivatives (79–82,
91, 97) did not show any significant cytotoxicity against QSG-7701 (IC50 > 40µM) [68].
Ursolic acid caused bax up-regulation and down-regulation of Bcl-2 and discharge from
mitochondria of cytochrome C to the cytosol. In addition, UA cleaved caspase-9 and reduced
mitochondrial membrane ability. Thus, UA induces apoptosis in MDA-MB-231 cells through both the
mitochondrial death pathway and a mechanism dependent on the extrinsic death receptor. Therefore,
ursolic acid could be used as a promising anti-cancer drug in treatment of breast cancer [99]. UA (1)
suppressed the proliferation of androgen-independent DU145 and androgen-dependent human
prostate cancer cells (LNCaP) through inhibition of NF-κB and STAT3 activation. Tumour growth
was suppressed significantly when four-week-old athymic BALB/c male nude mice inoculated with
DU145 cells were treated with (+)-UA (i.p., 200mg/kg, twice a week) for 6 weeks. No significant effects
on body weight were observed in mice [100]. Moreover, UA displayed an inhibitor effect through
the DNA binding capacity of STAT3, constitutive and inducible STAT3 phosphorylation. In fact, UA
therapy also displayed protein expression of cycline D1 and Bcl-2 in a dose-dependent way. In the G1
phase, UA quickly collected in the cell population at 50 mM, sucked by flow cytometry, confirming
that ursolic acid caused G1 in the regulation of the cell cycle [101].
Many clinical trials using chemical, subcutaneous, orthotopic human xenograft and randomly
transgenic tumour development designs have provided extensive proof that naturally existing and
synthetic UA products have chemopreventive and therapeutic effects. Liposomal ursolic acid (LUA)
was used as a fresh drug in normal young volunteers and in individuals with developed solid tumours
in order to determine the highest permitted level (MTD), dose-limiting toxicities (DLTs), and UA
pharmacokinetics. A total sample of LUA (11, 22, 37, 56, 74, 98 and 130 mg/m2) was given to 63 subjects
(4 patients, 35 healthy participants and 24 adults). For the first season, clinical information revealed
that LUA had manageable 98 mg/m2 MTD toxicity. The DLTs were predominantly diarrhoea and
hepatotoxicity. Furthermore, a linear pharmacokinetic profile was found in the ursolic acid liposomal
model [52]. UA is a promising antitumor agent. It can induce apoptosis in tumour cells, on one hand,
and stop ordinary cell transformation, on the other. It also interferes with countless proteins, including
those that directly serve the structure of DNA. It can prevent the development of many tumour cell
types and cause apoptosis. It has been shown that this compound acts at different phases of tumour
growth. It efficiently prevents angiogenesis, tumour cell intrusion, and metastasis. It is comparatively
non-toxic and can be used in clinical practice as a chemopreventive/chemoprotective product [102].
Therefore, it is evident that UA and its analogues are promising therapeutic agents against several
types of cancers.
4.3. Antibacterial
Public health is faced with many challenges, including the resistance of many already-available
antibiotics. There is hope in the use of naturally occurring products as a substitute that can produce a
better and more promising therapeutic effect through the discovery of new compounds and derivatives
against bacterial pathogens. Nascimento and colleagues (2014) semi-synthesized two analogues of
UA isolated from the Sambucus australis plant. Modifications of the UA structure were made at C-3
(hydroxyl group) to yield 3β-formyloxy-urs-12-en-28-oic acid (19) and 3β-acetoxy-urs-12-en-28-oic
acid (20), as shown in Figure 5. Ursolic acid and its analogues showed significant antibacterial and
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antioxidant properties. These authors tested the minimal inhibitory concentration (MIC) of both ursolic
acid and its derivatives against several microbial pathogen strains (Staphylococcus aureus, Bacillus
cereus, Shigella flexneri, two strains of Escherichia coli, Aeromonas caveae, Pseudomonas aeruginosa, Klebsiella
pneumonia, and Vibrio colareae) using the microdilution method. Compound 19 (64 µg/mL) when
combined with kanamycin showed significant activity towards Escherichia coli compared to the
multidrug resistance observed from sputum, which reduced MIC from 128 µg/mL to 8 µg/mL [64].
This shows that the antibacterial efficiency of UA improves with modification.
Wang and co-authors (2016), in their investigation, explored the biological antibacterial properties
of UA against Staphylococcus aureus (MRSA), which is resistant to methicillin. Researchers in this
research noted that with no haemolytic consequences, UA produced a reduction in staphylococcal
membrane integrity. UA-treated protein type relative to ordinary MRSA cells showed that UA
impacted translation efficiency, chaperon subunits, ribonuclease, oxidative reactions, and glycolysis
of a variety of proteins engaged in the transformation method [8]. Zhao and others (2018) isolated
ursolic acid from the leaves of Ilex hainanensis Merr. These authors assessed seven UA derivatives
against Fusobacterium nucleatum (Gram-ve) and Streptococcus mutans (Gram + ve) for their antibacterial
activity. Only three derivatives displayed important activity against Gram positive at distinct levels
and displayed substantial activity against Gram negative at a minimum inhibitor level (MIC) of
625 µg/mL [103]. Park and other researchers (2015) recorded the action of ursolic acid (UA) against
bacterial (Streptococcus mutans) development in their quest for powerful antimicrobial drugs [104].
4.4. Anti-Diabetes
Diabetes mellitus is a chronic disease that is triggered by insulin resistance or deficiency. This
disease is one of the major risks to human well-being worldwide [105]. Long-term use of oral
hypoglycaemic agents may reduce their pharmacological activity. Due to an utter glucose insufficiency,
type 1 diabetes mellitus (DM1) results in hyperglycaemia. This results in numerous problems,
including microvascular and macrovascular modifications in pathology, retinopathy, neuropathy,
diabetic nephropathy, diabetic osteopenia, and osteoporosis. Recent clinical studies have shown
that DM1 increases knee, vertebral, proximal humerus, tibia, shoulder and knee fracture hazards
independent of bone mineral thickness (BMD) [71]. Consequently, there is a growing interest in
scientific knowledge regarding, and clinical approval for the search for and use of, antidiabetic drugs
from natural sources. Ursolic acid is known to have a beneficial impact on lowering blood glucose
concentrations and on the healing of diabetic problems in diabetic mice. On the other hand, derivatives
of UA reduce protein tyrosine phosphatase 1B, improve phosphorylation of insulin receptors, and
stimulate glucose absorption [69].
Wu and colleagues (2014) produced a series of UA derivatives and evaluated their potency as
an antidiabetic agent against α-glucosidase. Most of the derivatives showed activity, except for one
compound with four derivatives showing significant inhibition at IC50 of 2.66 ± 0.84, 1.01 ± 0.44,
3.26 ± 0.21 and 3.24 ± 0.21 µM [106]. Wu and co-authors (2015) explored the antidiabetic activity of
several UA analogues against the α-glucosidase. These authors discovered that most of these analogues
exhibited significant inhibition activity, with the two highest potencies being IC50 = 1.27 ± 0.27 and IC50
= 1.28 ± 0.27 µM, compared to the other derivatives and the positive control [67]. Khusnutdinova and
others (2015) explored UA derivatives with respect to their medicinal effects (in vitro inhibition) against
α-glucosidase. 2,3-Indole UA derivative (107) showed a greater efficiency against α-glucosidase with
an IC50 value of 115.1 µM; 3,5 times more potent than the standard drug (acarbose) [69].
Yu and others (2015) reported the antidiabetic effects of UA derivatives in bone deteriorations (BMD)
of diabetic mice (6 weeks old) induced by streptozotocin (STZ). In this research study, UA derivative
(108) was used as hypoglycaemic agents to evaluate their therapeutic effects against non-obese type 2
diabetic mice for two weeks. In this study, biomarkers in serum and urine were measured. In addition,
protein expression, gene, and histomorphology analysis were measured from mice tibias. Moreover,
femurs were taken for bone Ca measurement and trabecular bone three-dimensional architecture.
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These authors revealed a reduced testosterone level in the STZ serum of mice. UA analogues showed
increased bone Ca, BMD, significantly increased Fibroblast growth factor 23 (FGF-23) and osteocalcin
(OCN), and reduced diabetic mice parathyroid hormone (PTH) levels and crosslaps (CTX). UAD
reversed the trabecular deleterious effects caused by STZ and stimulated remodelling of the bone.
Treatment with UAD for the STZ group significantly increased the osteoprotegerin (OPG)/nuclear
factor (NF)-κB ligand (RANKL) ratio. It has been shown that UA derivatives can improve STZ-induced
bone deterioration by improving the dysfunction of mesenchymal stem cells [71].
Chinese hamster ovary (CHO-K1) neurons with the TGR5 gene were transfected by Lo and others
(2017) to test the antidiabetic effects of UA. Using a fluorescent marker, the features of the transfected
cells were verified through glucose uptake. In addition, NCI-H716 cells that secreted incretin were
also explored, and ELISA sets were used to quantify the glucagon-like protein (GLP-1) concentrations.
In fact, Type 1-like diabetic rats induced by STZ were used to define the impact of in vitro ursolic acid.
The level of UA dependently enhanced glucose uptake in TGR5 producing CHO-K1 cells. UA caused
a concentration-dependent increase in GLP-1 secretion of NCI-H716 cells, which was inhibited by
triamterene at efficient levels to inhibit TGR5. Ursolic acid also improved the amount of GLP-1 plasma
by activating TGR5, which was further described in vitro with diabetic rats of type 1 [107].
4.5. Neuroprotective Activity
Neurological disorders include anxiety, depression, stroke and Alzheimer’s disease, among
others [64]. Long-term neurological outcomes cannot be improved by subarachnoid haemorrhage
(SAH) therapies that reduce the incidence of cerebral vasospasm, indicating that their importance
in patient outcome has been misinterpreted. More recently, early brain injury (EBI) was seen as the
primary cause of negative results in patients with SAH, rather than cerebral vasospasm. UA remains an
important and popular antioxidant reagent, with many reports suggesting that it has brain protective
effects against ischemic stroke [108]. Oxidative stress was identified as being among the complicated
causes associated with neuronal death after SAH. Reactive oxygen species (ROS) or reactive nitrogen
species (RNS), such as peroxynitrite (ONOO−), nitric oxide (NOO), superoxide anion (•O2), hydroxyl
radical (•OH), and hydrogen peroxide (H2O2), play a crucial role after SAH [109]. Several researchers
have shown that redox-sensitive Nrf2 activation has a central position in improving the endogenous
defence mechanism through which the brain protects itself against ischemic harm and recovers from
the stroke [110].
Sahni and co-workers (2016) reported that UA derivatives of C-6 (C-17 propyl amide) and C-2 (C-3
methyl ester) displayed important neuroprotective activity in an in vivo model of D-galactose-induced
neurotoxicity in rats. Thus, C-2 and C-6 could be advantageous in cognitive disorder therapy, for
instance, in the treatment of Alzheimer’s disease and dementia [66]. Li and colleagues (2012) reported
an interesting piece of research on the in vivo neuroprotective effect of UA on cerebral dischemia.
These researchers showed important and necessary anti-inflammatory and antioxidative effects of
UA in the brains of the mice after middle cerebral occlusion (MCAO) at 24 h [110]. Moreover, Zhang
and colleagues (2014) proposed in vivo effects of UA against EBI (neurological deficiency, blood–brain
barrier disruption, neural cell apoptosis, and brain edema) after SAH on Sprague Dawley rat models.
The effects of UA in reducing EBI could be explained by alleviation of oxidative stress on SD rats.
Therefore, UA might be regarded as a potential therapeutic agent for neurological disorders [108].
Another disease, known as Parkinson’s disease (PD), is a chronic progressive neurodegenerative
disorder that is defined both by motor and nonmotor characteristics. Through its progressive
degenerative impacts on mobility and muscle control, it has a major clinical effect on patients, families,
and caregivers [111]. PD is the second most common age-related progressive neurodegenerative disease,
following Alzheimer’s, and characterized by dopaminergic (DA) neuron reduction, α-synuclein protein
accumulation, and neuroinflammation [112–114]. Rai and others (2015) explored the neuroprotective
efficiency of UA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse models
(5 mg/kg, 25 mg/kg, and 50 mg/kg body weight). Immunostaining of substantia nigra dopaminergic
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cells was also conducted, as well as HPLC quantification of dopamine and its 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanilic acid (HVA) metabolites. In addition, these authors discovered that
UA increases cognitive deficits, restores modified dopamine levels (p < 0.001), and protects the
MPTP-intoxicated mouse’s dopaminergic neurons (p < 0.01). Among three distinct doses, the most
efficient dose for PD was 25 mg/kg body wt. [113]. The literature suggests that UA and its derivatives
can be considered to be potential therapeutic agents for neurological disorders.
4.6. Herbicidal Activity
Compounds with allelophatic potency are denoted as allelochemicals. Allelochemicals can cause
inhibition of photosynthesis, decreases in chlorophyll content, inhibition of enzymatic activity, and
disruption of the membrane and structure of cells. These effects can also be beneficial for host plants,
inhibiting the development of pathogenic fungus organisms as a result of their antibacterial, antifungal
and growth-inhibiting activities [115]. Phenolic compounds and their derivatives, particularly simple
phenols such as phenolic acids, affect the permeability of the membrane, inhibiting the growth
of the aerial part and the elongation of the roots [89]. Specifically, the IC50 values of UA range
between 75 and 700 µM for drastic growth of Lactuca sativa (lettuce) [89,116]. Tuyen et al. [74]
explored an interesting isolation and elucidation of a naturally occurring UA derivative called
2_,3_,7_,23-tetrahydroxyurs-12-ene-28-oic acid (118) from Castanea crenata (Japanese chestnut). These
authors reported the herbicidal effects of compound 118 in root and shoot growth of Echinochloa
crus-galli (barnyard grass), L. sativa, and Raphanus sativus (radish) p-hydroxybenzoic acid. Compound
118 inhibition (IC50 = 2.62 and 0.41 mM) was >5 times higher than p-hydroxybenzoic acid (IC50 = 15.33
and 2.11 mM) in the Echinochloa crus-galli shoot and root growth, respectively. These results indicate
that the isolated compound 118 has the ability to create natural herbicides for Echinochloa crus-galli
management [74].
The elder Sambucus nigra L. is a major berry crop plant globally that has been commonly converted
into jams, jellies and drinks commonly used in gastronomy, and which has previously been used
for its prospective health advantages [117,118]. Basas-Jaumandreu et al. [118] detected ursolic acid
in the leaves and inflorescences of S. nigra by means of Gas Chromatography with Electron Impact
Mass Spectrometry (GC-EIMS). UA (allelochemical) was most abundant in the leaves and flowers of
S. nigra (57 and 67%, respectively) [118]. In addition, Saidi et al. [115] studied the herbicidal activity of
triterpenoids isolated and elucidated UA from ethyl acetate flower extract of Citharexylum spinosum L.
including UA in germination and seedlings growth of plants such as R. sativus, L. sativa and Phalaris
canariensis (canary grass). The roots were the most adversely affected; UA (1) was the most phytotoxic
and caused 91.74 ± 0.24% and 89.55 ± 0.31% inhibition of roots and shoots, respectively [115].
UA was isolated and characterized from the Salvia syriaca L. methanol extract. Significant growth
inhibition (GI) of wheat seedlings was shown by UA, decreasing shoot lengths and Triticum aestivum
cv (wheat) seedling roots when evaluated at 0.2 mg/L (200 ppm) as reported by Abu-Irmaileh and
Abu-Zarga (2015). These authors reported UA GI (p = 0.05) on seed germination, root length and shoot
height of T. aestivum at 70%, 9.1 and 6 cm, respectively [119].
5. Conclusions
It is evident that the therapeutic activity of ursolic acid improves with modifications when
compared with various current used standard drugs. A majority of reports described increases
in the solubility, bioavailability, and potency of UA through modifications at different positions.
Many authors report modifications at the hydroxyl position C-3, hydrogen C-2, and carboxylic acid
position C-28. Although several synthetic ursolic acid inhibitors have already been submitted, fresh
derivatives still need to be developed and synthesized to further enhance their medicinal impacts on
non-communicable diseases. Therefore, UA and its derivatives provide hope as potential therapeutic
agents for non-communicable diseases through in vivo, in vitro, preclinical and clinical trials. Moreover,
UA and its derivatives possess herbicidal effects in the growth of various plants.
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